Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nuvation Bio Inc
NUVB | US
4.59
USD0.02
0.44%
NUVB | US
About Nuvation Bio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
06/03/2026
Close
4.59
Open
4.45
High
4.73
Low
4.43
Nuvation Bio Inc. a clinical-stage biopharmaceutical company focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868 a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation including oncogenes comprising c-myc; NUV-1156 an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs as well as NUV-1176 a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York New York.
View LessNUVB | US
Risk
98.3
Sharpe
1.43
Luna's Score
45/100
Recommendation
Sell
Luna says (NUVB | US)
What's Working
Strength based on increasing price with high volume
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
137.7%1 month
98.3%3 months
82.6%6 months
108.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.16
Debt to equity
1.13
Debt to assets
0.49
Ent. to EBITDA
2.23
Ent. to rev.
174.93
PEG
-
Other Fundamentals
EBITDA
-537.34M
MarketCap
1.54B
MarketCap(USD)
1.54B
Div. yield
-
Op. margin
-32.78K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-88.30
Short ratio
12.67
Short perc.
9.00
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.76
Range1M
2.06
Range3M
5.59
Volumes: Market Activity
Rel. volume
1.11
Price X volume
29.06M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.23 | - | Expensive |
| Ent. to Revenue | 174.93 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.16 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 82.60 | - | Par |
| Debt to Equity | 1.13 | -1.23 | Expensive |
| Debt to Assets | 0.49 | 0.25 | Expensive |
| Market Cap | 1.54B | - | Emerging |
